SCHEMBL2947441

SCHEMBL2947441

COC(=O)c1ccc2c(N)c(C(=O)Nc3ccc(Cl)cn3)oc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 0.53
▸ KMT2A Q03164 6/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ RECQL P46063 1/20 0.50
▸ RAB9A P51151 13/20 0.49
▸ NPC1 O15118 11/20 0.49
▸ TP53 P04637 4/20 0.49
▸ CYP2C19 P33261 3/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ NFKB1 P19838 4/20 0.47
▸ NFKB2 Q00653 4/20 0.47
▸ RELA Q04206 4/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPT P10636 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945609 0.92 SMN1; SMN2 (0.57) SMN1; SMN2KMT2AMEN1RECQLRAB9A
SCHEMBL13665241 0.89 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13665243 0.87 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13665204 0.87 RAB9A (0.55) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13291230 0.86 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AMEN1RECQLRAB9A
SCHEMBL13665212 0.85 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13665211 0.83 SORT1 (0.57) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13515797 0.83 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13515771 0.82 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL13665184 0.80 NPC1 (0.60) SMN1; SMN2KMT2AMEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US disclosed
CN-100439351-C Benzofuran derivative TANABE SEIYAKU CO (JP) 2008-12-03 — — CN disclosed
CN-100430392-C Carbamoyl-type benzofuran derivatives TANABE SEIYAKU CO (JP) 2008-11-05 — — CN disclosed
US-20060247273-A1 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-11-02 — — US disclosed
CN-1856488-A Carbamoyl-type benzofuran derivatives TANABE SEIYAKU CO (JP) 2006-11-01 — — CN disclosed
EP-1666478-A1 CARBAMOYL-TYPE BENZOFURAN DERIVATIVES TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 — — EP disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed
CN-1656086-A Benzofuran derivative TANABE SEIYAKU CO (JP) 2005-08-17 — — CN disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 SMN1; SMN2 3151/4885KMT2A 1500/4885MEN1 2756/4885
US-20060247273-A1 Carbamoyl-type benzofuran derivatives F12, F2, F3 SMN1; SMN2 4587/4885KMT2A 60/4885MEN1 1937/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885KMT2A 1518/4885MEN1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback